​​Fenwick & West represented Loxo Oncology, Inc. (Nasdaq: LOXO), a biopharmaceutical company focused on the development and commercialization of highly selective medicines for patients with genomically defined cancers, in its definitive agreement to be acquired by Eli Lilly and Company (NYSE: LLY). Under the terms of the agreement, Lilly will commence a tender offer to acquire all outstanding shares of Loxo Oncology for a purchase price of $235.00 per share in cash, or approximately $8.0 billion. The transaction is expected to close by the end of the first quarter of 2019, subject to customary closing conditions. More information about
Loxo Oncology’s acquisition by Lilly can be obtained from the company announcement.